source
- Eli Lilly to acquire cancer cell therapy startup Kelonia Therapeutics for $3.2 billionEli Lilly announced it will buy privately held Kelonia Therapeutics, a biotech focused on cell therapies for cancer and autoimmune diseases, in a deal valued at $3.2 billion. Kelonia has operated…
- Sanofi’s tolebrutinib receives EU CHMP endorsement for specific multiple sclerosis patients despite US FDA setbackSanofi's BTK inhibitor tolebrutinib is moving toward approval in the European Union for a subset of multiple sclerosis patients. The Committee for Medicinal Products for Human Use (CHMP) of the Eu…